HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08. August 2024 16:30 ET
|
HOOKIPA Pharma Inc.
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
08. Juli 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
01. Juli 2024 16:31 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
04. Juni 2024 13:00 ET
|
HOOKIPA Pharma Inc.
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with...
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
23. Mai 2024 17:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
25. April 2024 07:01 ET
|
HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback ...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
24. April 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10. April 2024 07:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22. März 2024 07:01 ET
|
HOOKIPA Pharma Inc.
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2...
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
29. Januar 2024 08:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights...